AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUN 12 - (NewsRx.com & NewsRx.net) -- Correlogic Systems, Inc., the developer of promising new cancer detection tests that use just a single drop of blood from a patient, has entered into an agreement with Advion BioSciences to explore the use of Advion's NanoMate System as a component of Correlogic's upcoming ovarian cancer clinical trials.
Correlogic's test, called Proteome Pattern Blood Test, scans a drop of blood for protein patterns generated by a mass spectrometer. In February 2002, Correlogic Systems earned international recognition when its joint research with the National Cancer Institute (NCI) and the U.S. Food and Drug Administration (FDA) revealed that the Correlogic test successfully detected all of the ovarian cancer patients in a study of 216 women, including cancers that were still in Stage 1. On April 9, 2003, NCI announced that Correlogic, NCI, and FDA scientists have achieved further improved results. The team was able to detect ovarian cancer with 100% accuracy - again identifying all of the cases of ovarian cancer - but without any false positives.
The goal ...
Source: HighBeam Research, NanoMate System may be used in new diagnostic.